End-of-day quote
Korea S.E.
23:00:00 29/04/2024 BST
5-day change
1st Jan Change
6,270
KRW
-.--%
+10.97%
-8.87%
03-27
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
03-18
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
Sales 2021
7.94B
5.82M
464M
Sales 2022
6.5B
4.76M
380M
Capitalization
69.4B
50.87M
4.06B
Net income 2021
-3.31B
-2.43M
-194M
Net income 2022
-4.49B
-3.29M
-263M
EV / Sales 2021
11.9
x
Net cash position
2021
5.4B
3.96M
316M
Net cash position
2022
835M
612K
48.82M
EV / Sales 2022
10.5
x P/E ratio 2021
-28.9
x
P/E ratio 2022
-15.4
x
Employees
-
Yield 2021 *
-
Yield 2022
-
Free-Float
63.73%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
03-26
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
03-17
CI
PanGen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
12/05/23
CI
PanGen Biotech Inc. announced that it has received KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
19/04/23
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
17/04/23
CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
21/11/22
CI
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor
10/06/21
CI
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor
02/06/21
CI
Huons Lab Forms Partnership with Pangen Biotech to Co-Develop Human Genetic Recombinant Hyaluronidase
15/12/19
CI
PanGen Biotech Inc.(KOSDAQ:A222110) dropped from S&P Global BMI Index
23/09/19
CI
CCM Duopharma Biotech Berhad completed the acquisition of 8.4% stake in PanGen Biotech Inc. from Chemical Company of Malaysia Berhad.
28/06/18
CI
CCM Duopharma Biotech Berhad entered into agreement to acquire PanGen Biotech Inc. from Chemical Company of Malaysia Berhad for KRW 16.4 billion.
12/04/18
CI
Chemical Companies In Talks To Sell Non Core Assets
02/03/18
CI
PanGen Biotech Inc. announced that it has received KRW 18 billion in funding
20/02/18
CI
PanGen Biotech Inc. announced that it expects to receive KRW 18 billion in funding
18/02/18
CI
More news
1 week +10.97%
Current month +0.16%
1 month +0.16%
3 months +1.62%
6 months +30.35%
Current year -8.87%
More quotes
Managers
Title Age Since
Chief Executive Officer
63
28/01/10
Director of Finance/CFO
58
30/11/10
Chief Tech/Sci/R&D Officer
54
28/01/10
Members of the board
Title Age Since
Director/Board Member
60
-
Chief Executive Officer
63
28/01/10
58
-
More insiders
Date
Price
Change
Volume
02/05/24
5,950
-5.10%
11,445
30/04/24
6,270
-.--%
12,027
29/04/24
6,270
+3.47%
14,873
26/04/24
6,060
+1.17%
13,071
25/04/24
5,990
+6.02%
7,110
End-of-day quote
Korea S.E., April 29, 2024
More quotes
Pangen Biotech Inc. is a Korea-based company primarily engaged in the bio pharmaceuticals development technology transfer services. The Company mainly provides contract services for the manufacture of bio pharmaceuticals, bio pharmaceuticals development technology transfer services for the manufacture of Chinese hamster ovary (CHO) cell lines and the process of products and gains royalty from the services. The Company also provides reagents which are used for the development of bio pharmaceuticals. In addition the Company is also engaged in the development of bio pharmaceuticals such as Biosimilar EPO, Recombinant Factor VIII and Biosimilar G-CSF. The Company provides its services within domestic market and to overseas markets such as China, India, Mexico, America and Europe.
More about the company
1st Jan change
Capi.
-8.87% 51.72M +26.28% 42.68B -3.99% 42.4B +45.32% 40.04B -6.20% 28.31B +6.36% 24.94B -21.47% 18.96B +27.58% 12.3B -2.75% 11.95B -2.02% 11.55B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1